The Valley Desk

NCT06590857 · Interventional trial

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Overall registry status Recruiting

Phase 1 · Phase 2

Conditions Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, ER+ Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Hormone-Sensitive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Cancer With Bone Involvement

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov